NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Ensysce Biosciences, Inc. ENSC
8 fiscal years on record · USD · FY2025 reported · SEC filings only
Growth
USD 5.1M
Revenue, FY2025 · full 8-year series below
Revenue $M
Net income $M
FY2025 · Revenue 5.1 · Net income -10.2
Compound annual growth
Revenue compounded at +5.2% a year over five years.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
−201 cents
lost on every revenue dollar
Operating margin
Net margin
FY2025 · Operating -202.1% · Net -200.8%
ROE
FY2019 · ROE -21.3%
The 8-year record
8 fiscal years
Every figure from documents filed with the SEC · USD
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | · | · |
| Operating income $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| EBITDA $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | · | · |
| Income tax $B | · | · | · | · | · | 0.0 | 0.0 | 0.0 |
| Net income $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | 0.0 |
| Free cash flow $B | −0.0 | · | · | · | · | · | · | · |
| EPS, diluted $ | −3.98 | −11.45 | −70.40 | −139.42 | −1.48 | 0.00 | −0.63 | −0.21 |
| Dividend / sh $ | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · | · |
| ROE % | · | · | · | · | · | · | −21.3 | 42.4 |
| Shares out B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.01 | 0.01 |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 2 failures in 31 reconciliationsAUDITED
Reconciled in 6 of 19 fiscal years. 45 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente2 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2018